Global impact of the first coronavirus disease 2019 (COVID-19) pandemic wave on vascular services

Vascular and Endovascular Research Network (VERN) COVER study collaborative*; Benson, Ruth

DOI:
[10.1002/bjs.11961](https://doi.org/10.1002/bjs.11961)

License:
Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Vascular and Endovascular Research Network (VERN) COVER study collaborative* & Benson, R 2020, 'Global impact of the first coronavirus disease 2019 (COVID-19) pandemic wave on vascular services', *British Journal of Surgery*, vol. 107, no. 11, pp. 1396-1400. <https://doi.org/10.1002/bjs.11961>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Global impact of the first coronavirus disease 2019 (COVID-19) pandemic wave on vascular services

The Vascular and Endovascular Research Network (VERN) COVER study collaborative*¹

Correspondence to: R. A. Benson, Department of Cancer and Genomics, University of Birmingham, Mindelsohn Way, Birmingham B15 2TH, UK (e-mail: r.a.benson@bham.ac.uk)

*Members of the VERN COVER study collaborative are co-authors of this study and are listed in *Appendix S1* (supporting information)

Paper accepted 7 July 2020

Published online in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.11961

Introduction

Coronavirus disease 2019 (COVID-19) has had a profound effect on the availability of surgical resources¹. Vascular services have been severely affected by these challenges. Some vascular societies have issued guidance on what operative case mix should be undertaken during the pandemic^{2–4}. These include adapting service provision for elective and urgent vascular presentations such as stroke and aortic aneurysm. However, the exact impact of the pandemic is still unknown⁵. The Vascular and Endovascular Research Network (VERN) is an established vascular research collaborative^{6–9} that responded rapidly to the pandemic by delivering the COVID-19 Vascular SERvice (COVER) study, an international prospective mixed-methodology project. The aim of the first part of the COVER study described here (tier 1) is to document fluctuations in vascular services globally during the first phase of the pandemic.

Methods

International guidelines on designing and reporting of surveys were used¹⁰. The study protocol is available online (<https://www.medrxiv.org/content/10.1101/2020.05.27.20114322v1>; ISRCTN 80453162).

A remote digital survey was developed by a global team of vascular healthcare professionals. Questions related to all aspects of vascular care, including staff availability, multidisciplinary team input, and personal protective equipment (PPE) (*Appendix S2*, supporting information). Results reported here are for the period 23 March to 3 May 2020, divided into three 2-week periods for comparison. Duplicate responses were removed.

International/continental comparisons were performed, where possible, to describe relative change in practice. A score of 0–3 was allocated to each answer based on perceived relative service reduction by 12 VERN healthcare professionals (0 represents no change and 3 the most significant change) (*Appendix S3*, supporting information).

Results

Overall, 465 completed survey responses were collected from 249 different units in 53 countries across six continents (*Table S1*, supporting information). *Fig. 1* shows all unit responses together with overall mean service reductions and worldwide response. The reductions in service measures for individual countries are shown in *Appendix S3* (supporting information).

Carotid surgery

Globally, 17.7 per cent of units offered intervention only to patients with crescendo transient ischaemic attacks, 43.5 per cent continued to offer surgery on a case-by-case basis, and 36.4 per cent made no changes to their carotid practice.

Aortic screening programmes

Of those units offering aortic aneurysm screening services, 45.8 per cent stopped all screening activities, 18.7 per cent continued a reduced programme, and 7.9 per cent continued screening as usual.

Aortic pathology

Thresholds for abdominal aortic aneurysm (AAA) repair were raised in the majority of centres; 11.7 per cent of vascular units limited surgery to AAA more than 6.5 cm in

Fig. 1 Global overall mean service reductions, worldwide response, and service reduction scores in the UK and the Americas

Grey circles represent centre responses, indicating more populated data at the start and end of the time period. Global overall mean vascular practice was already reduced at the start, remaining relatively steady throughout. Compared with this, vascular surgical units in the UK (lockdown date 23 March 2020) began to implement more significant reductions in services. These measures became steadily more significant until around the time when the pandemic peaked locally (between 10 and 20 April).

Table 1 Changes to management of lower-limb arterial pathology during the study period and overall

	Fortnight 1	Fortnight 2	Fortnight 3	Overall
No change	19.7	1.9	13.9	15.4
Increasing endovascular management	19.7	17.2	17.9	18.2
Increasing direct to amputation or palliation	19.7	19.7	25.4	23.6
Limit revascularization to tissue loss	18.9	14.7	15.6	16.3
Limit revascularization to severe rest pain or tissue loss only	19.7	26.7	24.3	23.6
Other	2.4	3.4	2.9	2.9

Values are percentages.

maximal diameter, 16.4 per cent to those above 7 cm, 25.1 per cent to symptomatic or ruptured AAA, and 2.3 per cent to AAA suitable for endovascular AAA repair (EVAR) only. Despite this, 25.1 per cent reported no change in practice. Access to EVAR out of hours was initially available to 8.5 per cent of responding units, increasing to 21.2 per cent in the following 4 weeks. Overall, only 14.2 per cent of units maintained a 24/7 EVAR service, 26.3 per cent maintained an 'in hours' service, 31.5 per cent offered EVAR for urgent cases only, and 18.5 per cent were able to run their service on an *ad hoc* basis only. Post-EVAR surveillance continued as normal in 24.6 per cent of units. However, 35.2 per cent had reduced availability and 31.8 per cent stopped

it completely. The majority of units (56.6 per cent) maintained their pathways for acute aortic syndromes (type B aortic dissection, penetrating aortic ulcer, and intramural haematoma). A small proportion (5.9 per cent) moved to conservative management only, 4.5 per cent were offering early endovascular surgery, and 26.6 per cent limited surgery to ruptures.

Lower limb

Changes to the management of lower-limb pathology are shown in Table 1 for each 2-week period. The majority of units began offering a greater proportion of major amputation or palliation rather than

attempting revascularization for chronic limb-threatening ischaemia, with 60.4% of units documenting a move to an endovascular-first treatment strategy, especially in critical limbs (rest pain or tissue loss).

Outpatient clinics

Some 27.5 per cent of units moved to a triage clinic system, and 29.0 per cent cancelled all planned outpatient clinics. Use of technology permitted 14.9 per cent of units to move to video or telephone clinics, with 18.7 per cent including subsequent triage for attendance if required. The use of 'hot' clinics (reserved for acute/urgent patients) increased during the pandemic, and 79.1 per cent of units reported using some form of hot clinic to accommodate vascular patients.

Multidisciplinary team meetings

Overall, 32.2 per cent of units that normally participated in a multidisciplinary team (MDT) continued with face-to-face meetings; 59.5 per cent stopped regular face-to-face meetings and, of those, 39.1 per cent did not replace them. Overall, 36.8 per cent moved to remote conferencing.

Staff redeployment

Globally, 5.5 per cent of senior surgeons were redeployed to support other specialties, compared with 53.5 per cent of junior vascular surgical staff.

Personal protective equipment

The majority (80.5 per cent) of units had PPE guidance in place. Some 26.2 per cent of units did not have access to adequate PPE at the start, compared with 17.5 per cent at the end of the period.

Discussion

The COVER study is the first international prospective study of unit-level vascular surgical practice during the COVID-19 pandemic. Findings from tier 1 suggest radical changes in practice in a range of services.

One notable change across participating vascular units is the reduction in AAA screening activity. The benefit of AAA screening, and the likelihood of finding a new AAA (less than 1.5 per cent)¹¹, must be balanced against the risk of COVID-19 transmission and allocation of resources. Given that the majority of units reported higher size

thresholds for AAA intervention, the chances of finding AAAs large enough to be considered for repair at this time are even lower. UK National AAA Screening Programme data suggest that 809 threshold AAAs are identified annually (2018)¹², which implies that there will be a UK backlog of approximately 130 AAAs relating to this 6-week study period, with resource implications after the pandemic. This will be replicated to some degree worldwide.

Another common finding is the reported preference for endovascular strategies to address aortic and peripheral arterial disease; this is thought to be based on a drive to minimize hospital stay and reduce demand on ICU beds^{13,14}. For EVAR, a paradigm has been created where, potentially, more EVAR is performed during the pandemic, but with a reduction in post-EVAR surveillance. There are important implications relating to the financial resources, operating time and staffing that will be required to catch up with missed scans and scheduled operations as services begin to resume. Vascular patients will be competing with the estimated 28 million operations cancelled or postponed during the peak of the pandemic¹⁵. For lower-limb pathology, the results of an increased endovascular approach on limb-related outcomes will also be important to follow.

MDT meetings support individual clinician decision-making by navigating complex decisions through a multifaceted approach. COVID guidelines²⁻⁴ have provided recommendations that potentially go against surgeons' usual inclinations. Anecdotally, patients who may have received active treatment before the pandemic were being palliated owing to the perceived high risk of intervention, especially if they tested positive for COVID-19. Strategies have moved towards endovascular management where open surgery would have been the surgeon's usual preference. Replacing a face-to-face MDT with virtual meetings has facilitated ongoing access to MDT support for such complex decision-making during this challenging period.

Despite the large number of units taking part, correlating individual country or regional data with dates of lockdown is challenging. Dates of lockdown were, however, similar for countries providing the majority of responses (UK, Germany, USA). All participating units entered lockdown in March 2020, and were in lockdown when the survey began. If there are any subsequent COVID-19 'waves' in areas that are 'past the peak'¹⁶⁻²¹, or in locations where the pandemic peak has yet to occur, these data will support vascular surgeons in terms of practice and the resources needed.

Acknowledgements

The VERN executive committee formally acknowledges the support of and collaboration with the following international groups and networks: Vascular Society of Great Britain and Ireland (VSGBI), Rouleaux Club (RC), GLOBALSurg, British Society of Endovascular Therapy (BSET), Singapore Vascular Surgical Collaborative (SingVasc), Vascupedia (European vascular education platform), VASCUNET (collaboration of vascular registries), Australian and New Zealand Vascular Trials Network (ANZVTN), Audible Bleeding (evidence-based podcast, USA), British Society of Interventional Radiology (BSIR), BSIR Trainees (BSIRT), International Working Group on the Diabetic Foot (IWGDF), European Society of Vascular Surgery (ESVS), European Vascular Surgeons in Training (EVST) and STAR-Surg (UK-based student surgical research network). They also thank S. Kandola and the Department of Research and Development at University Hospitals Coventry and Warwickshire NHS Trust (Coventry, UK), I. Cruikshanks and T. Koller for Spanish and German translations. These partner groups and colleagues have enabled dissemination of the study and participation from multiple nations worldwide, which has been invaluable in the success of the COVER study to date.

The study has received financial grant support from the VSGBI. The National Institute for Health Research (NIHR) provided salary support for the co-chief investigators (reference NIHR000359).

Disclosure: The authors declare no conflict of interest.

References

- 1 COVIDSurg Collaborative. Global guidance for surgical care during the COVID-19 pandemic. *Br J Surg* 2020; **107**: 1097–1103.
- 2 The Vascular Society for Great Britain and Ireland. *COVID-19 Virus and Vascular Surgery*; 2020. www.vascularsociety.org.uk/professionals/news/113/covid19_virus_and_vascular_surgery [accessed 8 May 2020].
- 3 Society for Vascular Surgery. *COVID-19 Resources for Members*; 2020. <https://vascular.org/news-advocacy/covid-19-resources#Guidelines&Tools> [accessed 10 May 2020].
- 4 American College of Surgeons. *COVID-19 Guidelines for Triage of Vascular Surgery Patients*; 2020. <https://www.facs.org/covid-19/clinical-guidance/elective-case/vascular-surgery> [accessed 25 April 2020].
- 5 Mirza AK, Manunga J, Skeik N. Indirect casualties of COVID-19: perspectives from an American vascular surgery practice at a tertiary care centre. *Br J Surg* 2020; **107**: e246.
- 6 The Vascular and Endovascular Research Network VERN Executive Committee. The COvid-19 Vascular sERvice (COVER) Study: an international Vascular and Endovascular Research Network (VERN) Collaborative Study assessing the provision, practice, and outcomes of vascular surgery during the COVID-19 pandemic. *Eur J Vasc Endovasc Surg* 2020; **60**: 156–157.
- 7 Gwilym BL, Saratzis A, Benson R, Forsythe R, Dovell G, Dattani N *et al.* Study protocol for the Groin wound Infection after Vascular Exposure (GIVE) audit and multicentre cohort study. *Int J Surg Protoc* 2019; **16**: 9–13.
- 8 Saratzis A, Jaspers NEM, Gwilym B, Thomas O, Tsui A, Lefroy R *et al.*; Vascular and Endovascular Research Network (VERN) Collaborators. Observational study of the medical management of patients with peripheral artery disease. *Br J Surg* 2019; **106**: 1168–1177.
- 9 Saratzis A, Joshi S, Benson RA, Bosanquet D, Dattani N, Batchelder A *et al.*; VERN collaborators. Acute kidney injury (AKI) in aortic intervention: findings from the Midlands Aortic Renal Injury (MARI) Cohort Study. *Eur J Vasc Endovasc Surg* 2020; **59**: 899–909.
- 10 Kelley K, Clark B, Brown V, Sitzia J. Good practice in the conduct and reporting of survey research. *Int J Qual Health Care* 2003; **15**: 261–266.
- 11 Oliver-Williams C, Sweeting MJ, Jacomelli J, Summers L, Stevenson A, Lees T *et al.* Safety of men with small and medium abdominal aortic aneurysms under surveillance in the NAAASP. *Circulation* 2019; **139**: 1371–1380.
- 12 Public Health England. *Abdominal Aortic Aneurysm Screening Programme: Standards Data Report April 2017 to March 2018* (Gateway number: GW-77). PHE Publications: London, 2019.
- 13 Patel R, Sweeting MJ, Powell JT, Greenhalgh RM; EVAR trial investigators. Endovascular *versus* open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial. *Lancet* 2016; **388**: 2366–2374.
- 14 Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I *et al.*; BASIL trial participants. Bypass *versus* Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. *J Vasc Surg* 2010; **51**(Suppl): 5S–17S.
- 15 COVIDSurg Collaborative. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans. *Br J Surg* 2020; <https://doi.org/10.1002/bjs.11746> [Epub ahead of print].
- 16 Mayol J, Fernández Pérez C. Elective surgery after the pandemic: waves beyond the horizon. *Br J Surg* 2020; <https://doi.org/10.1002/bjs.11688> [Epub ahead of print].
- 17 Vogler SA, Lightner AL. Rethinking how we care for our patients in a time of social distancing during the COVID-19 pandemic. *Br J Surg* 2020; **107**: 937–939.
- 18 Søreide K, Hallet J, Matthews JB, Schnitzbauer AA, Line PD, Lai PBS *et al.* Immediate and long-term impact of the COVID-19 pandemic on delivery of surgical services. *Br J Surg* 2020; <https://doi.org/10.1002/bjs.11670> [Epub ahead of print].

- 19 Jessop ZM, Dobbs TD, Ali SR, Combella E, Clancy R, Ibrahim N *et al.* Personal protective equipment (PPE) for surgeons during COVID-19 pandemic: a systematic review of availability, usage, and rationing. *Br J Surg* 2020; <https://doi.org/10.1002/bjs.11750> [Epub ahead of print].
- 20 Welsh Surgical Research Initiative (WSRI) Collaborative. Surgery during the COVID-19 pandemic: operating room suggestions from an international Delphi process. *Br J Surg* 2020; <https://doi.org/10.1002/bjs.11747> [Epub ahead of print].
- 21 Mowbray NG, Ansell J, Horwood J, Cornish J, Rizkallah P, Parker A *et al.* Safe management of surgical smoke in the age of COVID-19. *Br J Surg* 2020; <https://doi.org/10.1002/bjs.11679> [Epub ahead of print].

Supporting information

Additional supporting information can be found online in the Supporting Information section at the end of the article.